NCT04139330 is a Phase 2 clinical trial of NPC-06 in Acute Pain in Herpes Zoster, sponsored by Nobelpharma.

Who is sponsoring NCT04139330?

NCT04139330 is sponsored by Nobelpharma.

What drugs are being tested in NCT04139330?

Interventions in NCT04139330: NPC-06.

What condition does NCT04139330 study?

NCT04139330 studies Acute Pain in Herpes Zoster.

Is NCT04139330 still recruiting?

NCT04139330 is currently terminated. Last updated 1 July 2021.

Last reviewed 2021-07-01 · How we verify

NCT04139330

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

NPC-06 to Acute Pain in Herpes Zoster

Terminated Phase 2 Last updated 1 July 2021

What this trial tests

Phase 2 trial testing NPC-06 in Acute Pain in Herpes Zoster in 16 participants. Terminated before completion.

Timeline

21 November 2019

Primary endpoint
28 February 2021

28 February 2021

Quick facts

Lead sponsor	Nobelpharma
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	16
Start date	21 November 2019
Primary completion	28 February 2021
Estimated completion	28 February 2021
Sites	1 location across Japan

Drugs / interventions tested

NPC-06 — full drug profile →

Conditions studied

Acute Pain in Herpes Zoster — all drugs for Acute Pain in Herpes Zoster →

Sponsor

Nobelpharma — full company profile →

Who can join

20 and older, any sex, with Acute Pain in Herpes Zoster. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this trial is to investigate the efficiency of pain relief and the safety of NPC-06 for the acute pain in herpes zoster in the placebo-controlled double-blind parallel group trial, in addition to explore the effective concentration of NPC-06.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Efficacy and safety of intravenous fosphenytoin for patients with acute herpes zoster-associated pain: A placebo-controlled randomized trial.
Iseki M, Yamamoto T, Ogawa Y, Majima Y, et al · · 2024 · cited 5× · PMID 38149403 · DOI 10.1111/1346-8138.17054

Verify or expand the search:

Other trials of NPC-06

Trials testing the same drug.

NCT05480553 — NPC-06 to Pain Associated With Acute Herpes Zoster · Phase 3 · completed
NCT03773055 — Phase II Clinical Trial of NPC-06 in Patients With Neuropathic Pain in Cancer · Phase 2 · terminated

Other Nobelpharma trials

Trials by the same sponsor.

NCT05480553 — NPC-06 to Pain Associated With Acute Herpes Zoster · Phase 3 · completed
NCT05495425 — Clinical Study of NPC-12Y Gel in Patients With Skin Lesions Associated With TSC · Phase 3 · completed
NCT04671472 — Efficacy Confirmation Study of NPC-09 · Phase 3 · completed
NCT04642950 — A Phase II/III Study of Sargramostim · Phase 2, PHASE3 · completed
NCT04503863 — An Additional Study of NPC-22 in Healthy Adult Males · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04139330 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nobelpharma
Last refreshed: 1 July 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04139330.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing